摘要
目的:通过对上海市同济医院住院患者的华法林使用情况进行横断面调查,了解非瓣膜性心房颤动患者华法林使用现状。方法:入选2012年1月至2013年12月收治于我院的所有永久性心房颤动患者。使用CHADS2和CHA2DS2-VASc系统分别评分。统计和比较中、高危患者使用华法林实际情况。结果:共入选2 451例非瓣膜性心房颤动患者,1 716例(70.0%)患者CHADS2评分≥2分,其中服用华法林的有565例(32.92%);2 113例(86.1%)患者CHA2DS2-VASc评分≥2分,其中服用华法林的有569例(26.93%)。结论:临床实践中,心房颤动中、高危患者华法林使用率严重不足。
Objective： To describe guideline adherence and oral antithrombotic therapy with warfarin rates among real-life patients with non valve atrial fibrillation （NVAF） through a retrospective cohort study. Methods： The patients with permanent NVAF hospitalized in Shanghai Tongji Hospital from Jan 2012 to Dec 2013 were recruited. Proportion of warfarin usage was estimated in those patients with known NVAF who should be eligible for anticoagulation therapy. Analysis of the usage of warfarin was performed in middle-high risk patients. Results： Of 2 451 patients, 1 716 （70. 0%） were at intermediate and high risks according to CHADS2, and 2 113 （86. 1%） according to CHA2DS2 VASc. Only 565（32. 92%） and 569（26. 93%） were on warfarin according to CHADS2 and CHA2DS2-VASc, respectively. Conclusion： Warfarin has been significantly under-used in patients with known NVAF in real life.
出处
《国际心血管病杂志》
2015年第4期288-290,共3页
International Journal of Cardiovascular Disease
